CRISPR Therapeutics AG
For the period ended Jun 30, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a) Not applicable.
(b) Not applicable.
(c) From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended June 30, 2026, our officers and directors took the following actions with respect to Rule 10b5-1 trading agreements:
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| James R. Kasinger (General Counsel and Secretary) | Adoption(May 6, 2026) | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). | Sale of the Company’s common stock pursuant to the terms of the plan. | Active through May 31, 2027 | 93,632 |
| Raju Prasad, Ph.D.(Chief Financial Officer) | Adoption(June 9, 2026) | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). | Sale of the Company’s common stock pursuant to the terms of the plan. | Active through May 31, 2027 | 14,565 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.